Best Practice & Research Clinical Haematology
Volume 22, Issue 3 , Pages 409-429 , September 2009

Management of Drug Toxicities in Chronic Myeloid Leukaemia

  • Michael J. Mauro, MD (Associate Professor)

      Affiliations

    • Knight Cancer Institute, Center For Hematologic Malignancies, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, UHN-73C, Portland, OR 97239, USA
    • Corresponding Author InformationCorresponding author. Tel.: +503 494 0376; Fax: +503 494 7386.
    • ,
  • Michael W. Deininger, MD, PhD (Associate Professor)

      Affiliations

    • Knight Cancer Institute, Center For Hematologic Malignancies, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, BRB-511, Portland, OR 97239, USA
    • Tel.: +503 494 1603; Fax: +503 494 3688.

References 

  1. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. Apr 5 2001;344(14):1031–1037
  2. Peng B, Hayes M, Resta D, et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol. Mar 1 2004;22(5):935–942
  3. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. Mar 15 2002;99(6):1928–1937
  4. Cortes J, Giles F, O'Brien S, et al. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. Blood. 2003 Jul 1;102(1):83–86
  5. Kantarjian H, Talpaz M, O'Brien S, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood. Apr 15 2004;103(8):2873–2878
  6. Cortes JE, Baccarani M, Guilhot F, et al. First report of the TOPS study: a randomized Phase III trial of 400 mg vs 800 mg imatinib in patients with newly diagnosed, previously untreated CML in chronic phase using molecular endpoints. Haematologica. 2008;93:Abstract 402
  7. Larson RA, Druker BJ, Guilhot F, et al. Correlation of pharmacokinetic data with cytogenetic and molecular response in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib - an analysis of IRIS study data. ASH Annual Meeting Proceedings Blood. 2006;108:Abstract 429
  8. Larson RA, Druker BJ, Guilhot F, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood. 2008 Apr 15;111(8):4022–4028
  9. Picard S, Titier K, Etienne G, et al. Trough plasma imatinib concentrations are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. ASH Annual Meeting Proceedings Blood. 2006;108:Abstract 2141
  10. Forrest DL, Trainor S, Brinkman RR, et al. Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels. Leuk Res. 2009 Feb;33(2):271–275
  11. Mahon FX, Molimard M. Correlation between trough imatinib plasma concentration and clinical response in chronic myeloid leukemia. Leuk Res. 2009 Aug;33(8):1147–1148(Epub 2009 Apr 23)
  12. Blasdel C, Wang Y, Lagattuta T, et al. Therapeutic drug monitoring of imatinib and impact on clinical decision making. ASH Annual Meeting Proceedings Blood. 2006;108:Abstract 4820
  13. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006 Jun 15;354(24):2542–2551
  14. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006 Jun 15;354(24):2531–2541
  15. Hochhaus A, Kantarjian HM, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 2007 Mar 15;109(6):2303–2309
  16. Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol. 2008 Jul 1;26(19):3204–3212
  17. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. Dec 7 2006;355(23):2408–2417
  18. Hochhaus A, Druker B, Sawyers C, et al. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. Blood. 2008 Feb 1;111(3):1039–1043
  19. Silver RT, Cortes J, Waltzman R, et al. Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials. Haematologica. 2009 May;94(5):743–744
  20. Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007 Nov 15;110(10):3540–3546
  21. le Coutre P, Ottmann OG, Giles F, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood. 2008 Feb 15;111(4):1834–1839
  22. Guilhot F, Apperley J, Kim DW, et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood. 2007 May 15;109(10):4143–4150
  23. Cortes J, Rousselot P, Kim DW, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood. 2007 Apr 15;109(8):3207–3213
  24. Ottmann O, Dombret H, Martinelli G, et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood. 2007 Oct 1;110(7):2309–2315
  25. Hughes TP, Branford S, White DL, et al. Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy. Blood. 2008 Nov 15;112(10):3965–3973
  26. Marin D, Marktel S, Bua M, et al. Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa. Leukemia. 2003 Aug;17(8):1448–1453
  27. Jabbour E, Hochhaus A, le Coutre P, et al. Minimal cross-intolerance between nilotinib and imatinib in patients with imatinib-intolerant chronic myelogenous leukemia (CML) in chronic phase (CP) or accelerated phase (AP). ASCO Annual Meeting Proceedings J Clin Oncol. 2008;26:Abstract 7063
  28. Cortes J, O'Brien S, Borthakur G, et al. Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP). ASH Annual Meeting Proceedings Blood. 2008;112:Abstract 182
  29. Cortes J, O'Brien S, Jones D, et al. Efficacy of nilotinib (formerly AMN107) in patients (Pts) with newly diagnosed, previously untreated philadelphia chromosome (Ph)-positive chronic myelogenous leukemia in early chronic phase (CML-CP). ASH Annual Meeting Proceedings Blood. 2008;112:Abstract 446
  30. Marin D, Marktel S, Foot N, et al. Granulocyte colony-stimulating factor reverses cytopenia and may permit cytogenetic responses in patients with chronic myeloid leukemia treated with imatinib mesylate. Haematologica. Feb 2003;88(2):227–229
  31. Quintas-Cardama A, Kantarjian H, O'Brien S, et al. Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia. Cancer. Jun 15 2004;100(12):2592–2597
  32. Mauro MJ, Kurilik G, Balleisen S, et al. Myeloid growth factors for neutropenia during imatinib mesylate (STI571) therapy for CML: preliminary evidence of safety and efficacy. Blood. 2001;98:139a
  33. Ault P, Kantarjian H, Welch MA, et al. Interleukin 11 May improve thrombocytopenia associated with imatinib mesylate therapy in chronic Myelogenous leukemia. Leuk Res. Jun 2004;28(6):613–618
  34. Cortes J, O'Brien S, Quintas A, et al. Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase. Cancer. Jun 1 2004;100(11):2396–2402
  35. Quintas-Cardama A, Han X, Kantarjian H, et al. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood. 2009;Epub 5/4/09
  36. Deininger MW, O'Brien SG, Ford JM, et al. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol. Apr 15 2003;21(8):1637–1647
  37. Hazarika M, Jiang X, Liu Q, et al. Tasigna for chronic and accelerated phase Philadelphia chromosome–positive chronic myelogenous leukemia resistant to or intolerant of imatinib. Clin Cancer Res. 2008 Sep 1;14(17):5325–5331
  38. Brave M, Goodman V, Kaminskas E, et al. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin Cancer Res. 2008 Jan 15;14(2):352–359
  39. Quintás-Cardama A, Kantarjian H, O'brien S, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol. 2007 Sep 1;25(25):3908–3914
  40. de Lavallade H, Punnialingam S, Milojkovic D, et al. Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis. Br J Haematol. 2008 May;141(5):745–747
  41. Mustjoki S, Ekblom M, Arstila TP, et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia. 2009 Mar 19;23(8):1398–1405
  42. Ramar K, Potti A, Mehdi SA. Uncommon syndromes and treatment manifestations of malignancy: case 4. Periorbital edema and imatinib mesylate therapy for chronic myelogenous leukemia. J Clin Oncol. Jan 1 2003;21(1):172–173
  43. Esmaeli B, Prieto VG, Butler CE, et al. Severe periorbital edema secondary to STI571 (Gleevec). Cancer. Aug 15 2002;95(4):881–887
  44. Scheinfeld N. Imatinib mesylate and dermatology part 2: a review of the cutaneous side effects of imatinib mesylate. J Drugs Dermatol. Mar 2006;5(3):228–231
  45. Etienne G, Cony-Makhoul P, Mahon FX. Imatinib mesylate and gray hair. N Engl J Med. 2002 Aug 8;347(6):446
  46. Tsao AS, Kantarjian H, Cortes J, et al. Imatinib mesylate causes hypopigmentation in the skin. Cancer. 2003 Dec 1;98(11):2483–2487
  47. Marin D, Marktel S, Bua M, et al. The use of imatinib (STI571) in chronic myelod leukemia: some practical considerations. Haematologica. Sep 2002;87(9):979–988
  48. Berman E, Nicolaides M, Maki RG, et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med. 2006;354:2006–2013
  49. Osorio S, Noblejas AG, Duran A, et al. Imatinib mesylate induces hypophosphatemia in patients with chronic myeloid leukaemia in late chronic phase, and this effects is associated with response. Am J Hematol. 2007;82:394–395
  50. Grey A, O'Sullivan S, Reid JR, et al. Imatinib mesylate, increased bone formation, and secondary hyperparathyroidism. N Engl J Med. 2006;355:2494–2495
  51. Fitter S, Dewar AL, Kostakis P. Long-term imatinib therapy promotes bone formation in CML patients. Blood. 2008;111:2538–2547
  52. Jonsson S, Olsson B, Ohlsson C, et al. Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia. Haematologica. Jul 2008;93(7):1101–1103
  53. O'Sullivan S, Nat D, Callon K. Imatinib promotes osteoblast differentiation by inhibiting PDGFR signalling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms. J Bone Miner Res. 2007;22:1679–1689
  54. Dewar AL, Farrugia AN, Condina MR. Imatinib as a potential antiresorptive therapy for bone disease. Blood. 2006;107:4334–4337
  55. El Hajj Dib I, Gallet M, Mentaverri R, et al. Imatinib mesylate (Gleevec) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity. Eur J Pharmacol. 2006;551:27–33
  56. Cross TJ, Bagot C, Portmann B, et al. Imatinib mesylate as a cause of acute liver failure. Am J Hematol. Mar 2006;81(3):189–192
  57. Ridruejo E, Cacchione R, Villamil AG, et al. Imatinib-induced fatal acute liver failure. World J Gastroenterol. Dec 28 2007;13(48):pp. 6608–6611
  58. Novartis Pharmaceuticals Corporation; Gleevec (imatinib mesylate): prescribing information (online). Available from: http://www.pharma.us.novartis.com/product/pi/pdf/gleevec_tabs.pdf[accessed 22.05.09]
  59. Novartis Pharmaceuticals Corporation; Tasigna (nilotinib): prescribing information (online). Available from: http://www.pharma.us.novartis.com/product/pi/pdf/tasigna.pdf[accessed 22.05.09]
  60. Bristol Myers Squibb Corporation; Sprycel (dasatinib): prescribing information (online). Available from: http://packageinserts.bms.com/pi/pi_sprycel.pdf[accessed 22.05.09]
  61. Ramanathan RK, Egorin MJ, Takimoto CH, et al. Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. J Clin Oncol. Feb 1 2008;26(4):563–569
  62. Gibbons J, Egorin MJ, Ramanathan RK, et al. Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. J Clin Oncol. Feb 1 2008;26(4):570–576
  63. Gambacorti-Passerini C, le Coutre P, Zucchetti M, et al. Binding of imatinib by alpha(1)-acid glycoprotein. Blood. 2002 Jul 1;100(1):367–368
  64. O'Brien SG, Meinhardt P, Bond E, et al. Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia. Br J Cancer. Nov 17 2003;89(10):1855–1859
  65. Wang Y, Zhou L, Dutreix C, et al. Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia. Br J Clin Pharmacol. Jun 2008;65(6):885–892
  66. Hamada A, Miyano H, Watanabe H, et al. Interaction of imatinib mesilate with human P-glycoprotein. J Pharmacol Exp Ther. Nov 2003;307(2):824–828
  67. Kajita T, Higashi Y, Imamura M, et al. Effect of imatinib mesilate on the disposition kinetics of ciclosporin in rats. J Pharm Pharmacol. Jul 2006;58(7):997–1000
  68. Rezai K, Lokiec F, Grandjean I, et al. Impact of imatinib on the pharmacokinetics and in vivo efficacy of etoposide and/or ifosfamide. BMC Pharmacol. 2007;7:13
  69. Breccia M, Muscaritoli M, Cannella L, et al. Fasting glucose improvement under dasatinib treatment in an accelerated phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib. Leuk Res. 2008 Oct;32(10):1626–1628
  70. Kerkela R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med. Aug 2006;12(8):908–916
  71. Atallah E, Durand JB, Kantarjian H, et al. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood. Aug 15 2007;110(4):1233–1237
  72. Atallah E, Kantarjian H, Cortes J. In reply to ‘Cardiotoxicity of the cancer therapeutic agent imatinib mesylate’. Nat Med. Jan 2007;13(1):14;author reply 15–16
  73. Hatfield A, Owen S, Pilot PR. In reply to ‘Cardiotoxicity of the cancer therapeutic agent imatinib mesylate’. Nat Med. Jan 2007;13(1):13;author reply 15–16
  74. Verweij J, Casali PG, Kotasek D, et al. Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005. Eur J Cancer. Apr 2007;43(6):974–978
  75. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia v.2.2009. Available from: http://www.nccn.org[accessed 22.05.09]
  76. Pye SM, Cortes J, Ault P, et al. The effects of imatinib on pregnancy outcome. Blood. Jun 15 2008;111(12):5505–5508
  77. Choudhary DR, Mishra P, Kumar R, et al. Pregnancy on imatinib: fatal outcome with meningocele. Ann Oncol. Jan 2006;17(1):178–179
  78. Ali R, Ozkalemkas F, Ozcelik T, et al. Pregnancy under treatment of imatinib and successful labor in a patient with chronic myelogenous leukemia (CML). Outcome of discontinuation of imatinib therapy after achieving a molecular remission. Leuk Res. Aug 2005;29(8):971–973
  79. AlKindi S, Dennison D, Pathare A. Imatinib in pregnancy. Eur J Haematol. Jun 2005;74(6):535–537
  80. Buyukbayrak EE, Ergen B, Karsidag YK, et al. Pregnancy complicated with chronic myelogeneous leukemia (CML) successfully treated with imatinib: a case report. Arch Gynecol Obstet. Aug 2008;278(2):161–163
  81. Garderet L, Santacruz R, Barbu V, et al. Two successful pregnancies in a chronic myeloid leukemia patient treated with imatinib. Haematologica. Jan 2007;92(1):e9–10
  82. Heartin E, Walkinshaw S, Clark RE. Successful outcome of pregnancy in chronic myeloid leukaemia treated with imatinib. Leuk Lymphoma. Jun 2004;45(6):1307–1308
  83. Prabhash K, Sastry PS, Biswas G, et al. Pregnancy outcome of two patients treated with imatinib. Ann Oncol. Dec 2005;16(12):1983–1984
  84. Russell MA, Carpenter MW, Akhtar MS, et al. Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk. J Perinatol. Apr 2007;27(4):241–243
  85. Gambacorti-Passerini C, Tornaghi L, Marangon E, et al. Imatinib concentrations in human milk. Blood. Feb 2007;109:179
  86. Cortes J, O'Brien S, Ault P, et al. Pregnancy outcomes among patients with chronic myeloid leukemia treated with Dasatinib. ASH Annual Meeting Proceedings Blood. 2008;112:Abstract 32
  87. He K, Lago MW, Iyer RA, et al. Lacteal secretion, fetal and maternal tissue distribution of dasatinib in rats. Drug Metab Dispos. 2008 Dec;36(12):2564–2570
  88. Cortes J, O'Brien S, Kantarjian H. Discontinuation of imatinib therapy after achieving a molecular response. Blood. Oct 1 2004;104(7):2204–2205
  89. Hensley ML, Ford JM. Imatinib treatment: specific issues related to safety, fertility, and pregnancy. Semin Hematol. Apr 2003;40(2 Suppl. 2):21–25
  90. Ault P, Kantarjian H, O'Brien S, et al. Pregnancy among patients with chronic myeloid leukemia treated with imatinib. J Clin Oncol. Mar 1 2006;24(7):1204–1208

PII: S1521-6926(09)00033-4

doi: 10.1016/j.beha.2009.06.001

Best Practice & Research Clinical Haematology
Volume 22, Issue 3 , Pages 409-429 , September 2009

Article Tools

* Image Usage & Resolution